Skip to main content

Table 1 Characteristics of patients

From: Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study

Variable

Baseline when switching to taking TAF from TDF

Number of patients

70

Median age, year (interquartile range)

44 (37–49)

Male, n (%)

65 (92.9)

Median HIV-1 RNA, copies/mL (interquartile range)

< 40 (< 40 to < 40)

Median CD4 counts, cells/μL (interquartile range)

480 (332–627)

Third agent class drugs

 INSTI, n (%)

61 (87.1)

  Dolutegravir (DTG), n (%)

32 (45.7)

  Elvitegravir (EVG), n (%)

18 (25.7)

  Raltegravir (RAL), n (%)

11 (15.7)

 PI, n (%)

9 (12.9)

  Boosted darunavir (bDRV), n (%)

9 (12.9)

Median TDF duration, weeks (interquartile range)

274 (128–454)

Median serum creatinine, mg/dL (interquartile range)

0.84 (0.72–0.97)

Median eGFR, mL/min/1.73 m2 (interquartile range)

80.89 (68.12–92.02)

GFR categories, (mL/min/1.73 m2)a

G1 ( 90), %

27.1

 G2 (60–89), %

58.6

 G3a (45–59), %

12.9

 G3b (30–44), %

1.4

Median Uβ2MG, μg/L (interquartile range)

267 (114–869)

UP 1+ or 2+, %

6.0

Median BUN, mg/dL (interquartile range)

13.5 (11.0–16.0)

Median body weight, kg (interquartile range)

70.1 (60.8–75.9)

Median BMI, kg/m2 (interquartile range)

23.4 (21.3–26.1)

Median TG, mg/dL (interquartile range)

145 (91–230)

Hypertension, n (%)

10 (14.3)

Diabetes mellitus, n (%)

3 (4.3)

Abnormal lipid metabolism, n (%)

9 (12.9)

 Fibrate treatment, n (%)

5 (7.1)b

 Statin treatment, n (%)

4 (5.7)b

  1. TAF tenofovir alafenamide fumarate, TDF tenofovir disoproxil fumarate, HIV human immunodeficiency virus, RNA ribonucleic acid, CD4 cluster of differentiation 4+ T cell, INSTI integrase strand transfer inhibitor, PI protease inhibitor, eGFR estimated glomerular filtration rate, GFR glomerular filtration rate, Uβ2MG urinary β2-microglobulin, UP urine protein, BUN blood urea nitrogen, BMI body mass index, TG triglycerides
  2. aNo patients were categorized into G4 or G5
  3. bNo patient took these drugs together